SYNLOGIC, INC.
SYBX evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for SYBX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · SYBX
Synlogic, Inc. is a clinical-stage biotechnology company developing oral, GI-restricted medicines based on synthetic biology, with a lead Phase 3 candidate for phenylketonuria (PKU) and an early-stage pipeline for metabolic disorders.
Key risk: Limited cash runway
BioSniper Score
Based on 5 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 3 pipeline candidates for SYNLOGIC, INC..
Synlogic, Inc. is a clinical-stage biotechnology company developing oral, GI-restricted medicines based on synthetic biology, with a lead Phase 3 candidate for phenylketonuria (PKU) and an early-stage pipeline for metabolic disorders.
- Lead candidate labafenogene marselecobac (SYNB1934) is being studied in Synpheny-3, a pivotal Phase 3 trial for PKU [sec_mda · as of 2025-11-13].
- SYNB1353, a potential treatment for homocystinuria (HCU), achieved proof of mechanism in a Phase 1 study in healthy volunteers [sec_mda · as of 2025-11-13].
- Cash and equivalents were $13.2M as of 2026-06-30, with zero revenue and a net loss of $0.5M for the period [sec].
- The company was founded in 2014 based on technology from the Massachusetts Institute of Technology (MIT) [sec_mda · as of 2025-11-13].
- The platform leverages fermentation and lyophilization for manufacturing, aiming for straightforward shipping, distribution, and storage [sec_mda · as of 2025-11-13].
What works
- Lead PKU candidate is in a pivotal Phase 3 trial, representing a potential near-term regulatory catalyst [sec_mda · as of 2025-11-13].
- Platform uses familiar manufacturing processes (fermentation, lyophilization) which may facilitate scale-up and reduce development risk [sec_mda · as of 2025-11-13].
- Early pipeline includes candidates for HCU (Phase 1 proof-of-mechanism achieved), enteric hyperoxaluria, gout, and cystinuria, providing multiple shots on goal [sec_mda · as of 2025-11-13].
What to weigh
- Cash position of $13.2M as of 2026-06-30 is limited, and the company has no approved products or revenue, creating funding risk [sec].
- The company is actively seeking strategic transactions, business combinations, or divestitures, indicating potential uncertainty about standalone viability [sec_mda · as of 2025-11-13].
- There is no assurance that any strategic transaction will enhance shareholder value or that the company will secure additional financing [sec_mda · as of 2025-11-13].
- The company has a history of operating losses and negative cash flows, with net cash used in operations of $25.3 million in the nine months ended September 30, 2024 [sec_mda · as of 2025-11-13].
From the filings
Quoted directly from source documents.
Lead candidate is in a pivotal Phase 3 study for PKU.
“Labafenogene marselecobac (SYNB1934), which was being studied in Synpheny-3, a pivotal, Phase 3 study for the treatment of patients with PKU”
SEC MD&A · November 13, 2025
SYNB1353 achieved proof of mechanism in Phase 1 for HCU.
“SYNB1353, a potential treatment for HCU, has achieved proof of mechanism in a Phase 1 study in healthy volunteers”
SEC MD&A · November 13, 2025
The company is exploring strategic transactions.
“allow sufficient opportunity to pursue and consummate one or more such transactions and to consider additional alternatives that may materialize in the future”
SEC MD&A · November 13, 2025
Risks & what to watch (4)›
Key risks
- Limited cash runway — Cash of $13.2M as of 2026-06-30 may not sustain operations beyond 12 months without additional funding or a strategic transaction [sec].
- No approved products or revenue — The company has zero revenue and relies on external financing or partnerships to continue operations [sec].
- Clinical trial risk — Phase 3 PKU trial and early-stage pipeline candidates may fail to meet endpoints, delaying or preventing regulatory approval [sec_mda · as of 2025-11-13].
- Strategic transaction uncertainty — Pursuit of business combinations or divestitures may not result in value-enhancing agreements or may dilute existing shareholders [sec_mda · as of 2025-11-13].
What to watch
- Top-line data from the Synpheny-3 Phase 3 trial for SYNB1934 in PKU [sec_mda · as of 2025-11-13].
- Updates on strategic alternatives, including potential partnerships, mergers, or asset sales [sec_mda · as of 2025-11-13].
- Progress of SYNB1353 in HCU and advancement of preclinical candidates for enteric hyperoxaluria, gout, and cystinuria [sec_mda · as of 2025-11-13].
- Cash burn rate and any new financing or capital-raising activities [sec].
Sources: SEC MD&A · Generated August 19, 2026 · How we verify sources →
Run SYNLOGIC, INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available SYNLOGIC, INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
43.1 months
D/E 0.12 · 0% dilution
Lead: Phase 3
3 candidates
No upcoming catalysts tracked
1 buy · 0 sells (180d)
Runway
Pipeline
Financials
Short Interest
as of Apr 22, 2026- % of float
- 0.2%
- Days to cover
- 0.1
- Shares short
- 10,406
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
SYBX short interestGovernance
Frequently asked questions
What is the AI investment thesis for SYNLOGIC, INC.?
Synlogic, Inc. is a clinical-stage biotechnology company developing oral, GI-restricted medicines based on synthetic biology, with a lead Phase 3 candidate for phenylketonuria (PKU) and an early-stage pipeline for metabolic disorders.
What is SYNLOGIC, INC.'s lead drug candidate?
SYNLOGIC, INC.'s most advanced tracked candidate is labafenogene marselecobac (Phase 3) for phenylketonuria (PKU).
Who is the CEO of SYNLOGIC, INC.?
Aoife M. Brennan is the chief executive officer of SYNLOGIC, INC. (SYBX).
Where is SYNLOGIC, INC. headquartered?
SYNLOGIC, INC. (SYBX) is headquartered in Winchester, MA, United States.
What therapeutic areas does SYNLOGIC, INC. focus on?
SYNLOGIC, INC. develops therapies across Rare Disease, Metabolic.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.